CD163 and breast carcinoma: Subsequent analysis using a publicly-available dataset revealed that the coordinated low-expression of CD163 and CXCR4 with high expression of THBS1 in 161 breast cancer tissues identified patients with TNBC (basal) having a high risk of recurrence and poor survival rate.